• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday

    2/26/24 11:18:56 AM ET
    $KOS
    $LUNR
    $MGNX
    $MRNA
    Oil & Gas Production
    Energy
    Industrial Machinery/Components
    Industrials
    Get the next $KOS alert in real time by email

    U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday.

    Shares of Surgery Partners, Inc. (NASDAQ:SGRY) fell sharply during Monday’s session following weak quarterly sales.

    Surgery Partners posted adjusted earnings of 44 cents per share, versus market estimates of 38 cents per share. The company’s quarterly sales came in at $735.40 million missing expectations of $741.40 million, according to data from Benzinga Pro.

    Surgery Partners shares tumbled 7.8% to $30.43 on Monday.

    Here are some other big stocks recording losses in today’s session.

    • Intuitive Machines, Inc. (NASDAQ:LUNR) dipped 25.1% to $7.18 after the company said its lunar lander may have tipped over upon landing on the moon.
    • Nyxoah S.A. (NASDAQ:NYXH) fell 11.3% to $15.29. Nyxoah is expected to release fourth quarter financial results on March 5, 2024.
    • Jin Medical International Ltd. (NASDAQ:ZJYL) fell 11.2% to $6.30.
    • TransMedics Group, Inc. (NASDAQ:TMDX) dipped 8.6% to $75.99. TransMedics Group is expected to release financial results for the fourth quarter after market close on Feb. 26, 2024.
    • World Acceptance Corporation (NASDAQ:WRLD) declined 7% to $120.71. World Acceptance recently reported better-than-expected third-quarter financial results.
    • MacroGenics, Inc. (NASDAQ:MGNX) fell 7% to $16.88.
    • Kosmos Energy Ltd. (NYSE:KOS) dipped 7% to $5.55. Kosmos Energy reported a fourth-quarter fiscal 2023 revenue decline of 10% year-over-year to $507.81 million, beating the consensus of $477.73 million.
    • Orla Mining Ltd. (NASDAQ:ORLA) fell 6.8% to $3.38.
    • Insulet Corporation (NASDAQ:PODD) fell 5.8% to $173.54 after Barclays maintained an Equal-Weight rating on the stock and lowered its price target from $214 to $213.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) declined 5.6% to $4.38.
    • Moderna, Inc. (NASDAQ:MRNA) fell 4.3% to $92.36 after HSBC downgraded the stock from Hold to Reduce but raised its price target from $75 to $86.

     

    Now Read This: Top 3 Defensive Stocks That May Collapse In February

    Get the next $KOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KOS
    $LUNR
    $MGNX
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Insulet Corporation
    $PODD
    1/27/2026$294.00Hold
    TD Cowen
    Insulet Corporation
    $PODD
    1/12/2026$274.00Overweight → Equal Weight
    Barclays
    Intuitive Machines Inc.
    $LUNR
    1/9/2026$20.00Buy → Hold
    Stifel
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Intuitive Machines Inc.
    $LUNR
    12/19/2025$20.00Overweight
    KeyBanc Capital Markets
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Insulet Corporation
    $PODD
    12/16/2025$370.00Outperform
    Evercore ISI
    More analyst ratings

    $KOS
    $LUNR
    $MGNX
    $MRNA
    SEC Filings

    View All

    SEC Form 424B3 filed by Kosmos Energy Ltd.

    424B3 - Kosmos Energy Ltd. (0001509991) (Filer)

    3/10/26 4:06:04 PM ET
    $KOS
    Oil & Gas Production
    Energy

    SEC Form 144 filed by World Acceptance Corporation

    144 - WORLD ACCEPTANCE CORP (0000108385) (Subject)

    3/10/26 12:21:06 PM ET
    $WRLD
    Finance: Consumer Services
    Finance

    MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MACROGENICS INC (0001125345) (Filer)

    3/9/26 4:12:10 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KOS
    $LUNR
    $MGNX
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Calmes John L Jr sold $141,880 worth of shares (1,000 units at $141.88), decreasing direct ownership by 2% to 50,334 units (SEC Form 4)

    4 - WORLD ACCEPTANCE CORP (0000108385) (Issuer)

    3/11/26 11:54:49 AM ET
    $WRLD
    Finance: Consumer Services
    Finance

    Chief Executive Officer Evans Jason Eric sold $158,061 worth of shares (11,462 units at $13.79) and was granted 278,106 shares, increasing direct ownership by 40% to 940,786 units (SEC Form 4)

    4 - Surgery Partners, Inc. (0001638833) (Issuer)

    3/9/26 7:33:25 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Chief Admin & Dev Officer Baldock Jennifer was granted 106,307 shares and sold $138,123 worth of shares (10,082 units at $13.70), increasing direct ownership by 41% to 332,272 units (SEC Form 4)

    4 - Surgery Partners, Inc. (0001638833) (Issuer)

    3/9/26 7:33:13 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    $KOS
    $LUNR
    $MGNX
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MARGENZA

    Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

    12/20/20 4:31:01 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOS
    $LUNR
    $MGNX
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autonomous Warfare Technologies Propel AI Defense Market Toward $30 Billion

    Rising geopolitical tensions, next-generation autonomous weapons systems, and rapid AI integration across defense platforms are projected to drive the market past $29 billion by 2035NEW YORK, March 11, 2026 /CNW/ -- Market News Updates News Commentary - The autonomous AI defense market is experiencing rapid growth as militaries increasingly integrate artificial intelligence, robotics, and machine learning into operational systems. Autonomous AI technologies enable defense platforms--such as drones, surveillance systems, and autonomous combat vehicles--to operate with minimal human intervention while enhancing decision-making speed, situational awareness, and mission efficiency. Governments a

    3/11/26 9:00:00 AM ET
    $AVAV
    $KTOS
    $LUNR
    Aerospace
    Industrials
    Military/Government/Technical
    Industrial Machinery/Components

    Kosmos Energy Announces Pricing of Public Offering of Common Stock

    DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Kosmos Energy Ltd. ("Kosmos" or the "Company") (NYSE/LSE:KOS) announced today the pricing of its registered underwritten public offering of 97,500,000 shares of common stock (the "Offering") at a price to the public of $1.90, resulting in gross proceeds to Kosmos of $185,250,000. In addition, Kosmos has granted the underwriters a 30-day option to purchase up to an additional 14,625,000 shares of common stock at the public offering price less underwriting discounts. The Offering is expected to close on March 12, 2026, subject to customary closing conditions. Kosmos intends to use the net proceeds from this offering to repay outstanding borrowings

    3/10/26 9:59:19 PM ET
    $KOS
    Oil & Gas Production
    Energy

    Kosmos Energy Announces Launch of Public Offering of Common Stock

    DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Kosmos Energy Ltd. ("Kosmos" or the "Company") (NYSE/LSE:KOS) announced today that it has launched a registered underwritten public offering of $175,000,000 of shares of common stock (the "Offering"). In addition, Kosmos intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of common stock at the public offering price less underwriting discounts. Kosmos intends to use the net proceeds from this offering to repay outstanding borrowings under its commercial debt facility and repayment of additional outstanding debt. Barclays and Stifel are acting as joint book-running managers in the Offering. The

    3/10/26 4:03:08 PM ET
    $KOS
    Oil & Gas Production
    Energy

    $KOS
    $LUNR
    $MGNX
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen resumed coverage on Insulet with a new price target

    TD Cowen resumed coverage of Insulet with a rating of Hold and set a new price target of $294.00

    1/27/26 8:46:58 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet downgraded by Barclays with a new price target

    Barclays downgraded Insulet from Overweight to Equal Weight and set a new price target of $274.00

    1/12/26 8:59:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $KOS
    $LUNR
    $MGNX
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Minogue Michael R bought $499,847 worth of shares (2,030 units at $246.23) (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/26/26 7:05:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    President and CEO Mcevoy Ashley bought $1,029,205 worth of shares (4,300 units at $239.35), increasing direct ownership by 45% to 13,916 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/23/26 8:14:32 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Stonesifer Timothy C. bought $299,884 worth of shares (962 units at $311.73), increasing direct ownership by 27% to 4,591 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/8/25 4:02:55 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $KOS
    $LUNR
    $MGNX
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Orla Mining Appoints Joanna Pearson as Independent Non-Executive Director

    VANCOUVER, BC, Dec. 16, 2025 /CNW/ - Orla Mining Ltd. (TSX:OLA) (NYSE:ORLA) ("Orla" or the "Company") is pleased to announce the appointment of Ms. Joanna Pearson to its Board of Directors as an Independent Non-Executive Director, effective immediately. Ms. Pearson has over 25 years of international experience in financial reporting, risk management, and strategic financial transformation in the mining sector. Her executive experience includes serving as Chief Financial Officer of Endeavour Mining plc from 2020 to 2023. Prior to this, she was an Audit Partner with Deloitte LLP

    12/16/25 6:00:00 AM ET
    $ORLA
    Precious Metals
    Basic Materials

    World Acceptance Corporation Announces the Retirement of Chief Branch Operations Officer D. Clinton Dyer

    World Acceptance Corporation (NASDAQ:WRLD) ("World Acceptance" or "the Company") today announced the planned retirement of D. Clinton Dyer, the Company's Executive Vice President and Chief Branch Operations Officer, following an extraordinary 30-year career with the organization. During his three decades with World Acceptance, Mr. Dyer helped shape and strengthen the Company's branch operations through steadfast leadership, deep operational knowledge, and a genuine commitment to the customers and communities the Company serves. "Clint has been a pillar of the Company for thirty years," said Chad Prashad, the Company's President and Chief Executive Officer. "His leadership, dedication, and

    12/4/25 7:30:00 AM ET
    $WRLD
    Finance: Consumer Services
    Finance

    $KOS
    $LUNR
    $MGNX
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Intuitive Machines Inc.

    SC 13D/A - Intuitive Machines, Inc. (0001844452) (Subject)

    11/20/24 5:01:02 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intuitive Machines Inc.

    SC 13G/A - Intuitive Machines, Inc. (0001844452) (Subject)

    11/14/24 7:05:51 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    $KOS
    $LUNR
    $MGNX
    $MRNA
    Financials

    Live finance-specific insights

    View All

    Ortelius Delivers Open Letter to Surgery Partners Stockholders

    Surgery Board and Management Team Have Presided Over the Vast Destruction of Value and Must Be Held Accountable Letter Outlines Multiple Paths to Building and Unlocking Intrinsic Value for Stockholders Divestiture of Surgical Hospitals Should Generate Billions of Dollars in Asset Sales, Enabling Stock Repurchase and Balance Sheet Deleveraging Ortelius Advisors, L.P. today issued the following open letter to stockholders of Surgery Partners, Inc. (NASDAQ:SGRY). March 10, 2026 Fellow Stockholders, Ortelius Advisors, L.P. ("Ortelius" or "we") believes that Surgery Partners, Inc. ("Surgery" or the "Company") has significant upside potential, based on its high-quality assets, favorab

    3/10/26 11:00:00 AM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

    Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or

    3/5/26 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2025 Results; Sets 2026 Guidance; Announces Share Repurchase Program

    BRENTWOOD, Tenn., March 02, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 2.4% for the fourth quarter and 6.2% for the full year Same-facility revenues increased 3.5% for the fourth quarter and 4.9% for the full year Surgical cases decreased 2.1% for the fourth quarter and increased 2.0% for the full year Same-facility cases increased 1.3% for the fourth

    3/2/26 4:05:00 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care